Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Validation of the REM sleep behavior disorder screening questionnaire in the Czech population

J. Bušková, P. Peřinová, E. Miletínová, P. Dušek, E. Růžička, K. Šonka, D. Kemlink,

. 2019 ; 19 (1) : 110. [pub] 20190604

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19034520

Grantová podpora
16-28914A Ministerstvo Zdravotnictví Ceské Republiky
16-07879S, project Nr. LO1611 Grantová Agentura České Republiky (CZ)
PROGRES Q35 Univerzita Karlova v Praze
PROGRES Q27/LF1 Univerzita Karlova v Praze
NV16-28914A MZ0 CEP - Centrální evidence projektů

BACKGROUND: Idiopathic rapid eye movement sleep behavior disorder (iRBD) affects 1-2% of people over 60 years of age and presents a high risk of developing a neurodegenerative disorder from the group of synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Therefore, screening tools are needed. In 2007, the rapid eye movement sleep behavior disorder screening questionnaire (RBD-SQ) was developed and has been translated into several languages. The aim of study was to assess the validity and reliability of the Czech version of the RBD-SQ in a mixed population of sleep clinic patients, supplemented by healthy volunteers and RBD patients. METHODS: Participants included 81 iRBD patients, 205 patients with other sleep disorders (obstructive sleep apnea, insomnia, restless legs syndrome and periodic limb movement disorder, other parasomnias, or central hypersomnias including narcolepsy) and 20 healthy volunteers. RESULTS: The mean RBD-SQ score in the iRBD patients was 9.4 ± 2.8 points, and in the non-RBD group it was 4.5 ± 3.0 (P < 0.0001). Receiver -operator analysis yielded an area under the curve of 0.864, suggesting good diagnostic performance of the scale. When using a cut-off value for positivity of 5 points, sensitivity was 0.89 and specificity was 0.62. CONCLUSIONS: The Czech version of the RBD-SQ is a sensitive tool for screening for iRBD patients and helps to identify subjects for complete clinical workup.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034520
003      
CZ-PrNML
005      
20191010121847.0
007      
ta
008      
191007s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12883-019-1340-4 $2 doi
035    __
$a (PubMed)31164104
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bušková, Jitka $u Department of Sleep Medicine, National Institute of Mental Health, Klecany, Czech Republic.
245    10
$a Validation of the REM sleep behavior disorder screening questionnaire in the Czech population / $c J. Bušková, P. Peřinová, E. Miletínová, P. Dušek, E. Růžička, K. Šonka, D. Kemlink,
520    9_
$a BACKGROUND: Idiopathic rapid eye movement sleep behavior disorder (iRBD) affects 1-2% of people over 60 years of age and presents a high risk of developing a neurodegenerative disorder from the group of synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Therefore, screening tools are needed. In 2007, the rapid eye movement sleep behavior disorder screening questionnaire (RBD-SQ) was developed and has been translated into several languages. The aim of study was to assess the validity and reliability of the Czech version of the RBD-SQ in a mixed population of sleep clinic patients, supplemented by healthy volunteers and RBD patients. METHODS: Participants included 81 iRBD patients, 205 patients with other sleep disorders (obstructive sleep apnea, insomnia, restless legs syndrome and periodic limb movement disorder, other parasomnias, or central hypersomnias including narcolepsy) and 20 healthy volunteers. RESULTS: The mean RBD-SQ score in the iRBD patients was 9.4 ± 2.8 points, and in the non-RBD group it was 4.5 ± 3.0 (P < 0.0001). Receiver -operator analysis yielded an area under the curve of 0.864, suggesting good diagnostic performance of the scale. When using a cut-off value for positivity of 5 points, sensitivity was 0.89 and specificity was 0.62. CONCLUSIONS: The Czech version of the RBD-SQ is a sensitive tool for screening for iRBD patients and helps to identify subjects for complete clinical workup.
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a plošný screening $x metody $7 D008403
650    _2
$a lidé středního věku $7 D008875
650    _2
$a porucha chování v REM spánku $x diagnóza $7 D020187
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a senzitivita a specificita $7 D012680
650    12
$a průzkumy a dotazníky $7 D011795
650    _2
$a překládání $7 D014175
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a validační studie $7 D023361
700    1_
$a Peřinová, Pavla $u Department of Neurology and Center of Clinical Neurosciences, 1stFaculty of Medicine, Charles University, Kateřinská 30, 12000, Praha 2, Czech Republic.
700    1_
$a Miletínová, Eva $u Department of Sleep Medicine, National Institute of Mental Health, Klecany, Czech Republic.
700    1_
$a Dušek, Petr $u Department of Neurology and Center of Clinical Neurosciences, 1stFaculty of Medicine, Charles University, Kateřinská 30, 12000, Praha 2, Czech Republic.
700    1_
$a Růžička, Evžen $u Department of Neurology and Center of Clinical Neurosciences, 1stFaculty of Medicine, Charles University, Kateřinská 30, 12000, Praha 2, Czech Republic.
700    1_
$a Šonka, Karel $u Department of Neurology and Center of Clinical Neurosciences, 1stFaculty of Medicine, Charles University, Kateřinská 30, 12000, Praha 2, Czech Republic.
700    1_
$a Kemlink, David $u Department of Neurology and Center of Clinical Neurosciences, 1stFaculty of Medicine, Charles University, Kateřinská 30, 12000, Praha 2, Czech Republic. david.kemlink@vfn.cz.
773    0_
$w MED00008195 $t BMC neurology $x 1471-2377 $g Roč. 19, č. 1 (2019), s. 110
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31164104 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191010122305 $b ABA008
999    __
$a ok $b bmc $g 1451180 $s 1073070
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 19 $c 1 $d 110 $e 20190604 $i 1471-2377 $m BMC neurology $n BMC Neurol $x MED00008195
GRA    __
$a 16-28914A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a 16-07879S, project Nr. LO1611 $p Grantová Agentura České Republiky (CZ)
GRA    __
$a PROGRES Q35 $p Univerzita Karlova v Praze
GRA    __
$a PROGRES Q27/LF1 $p Univerzita Karlova v Praze
GRA    __
$a NV16-28914A $p MZ0
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...